Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

Tourmaline Bio, Inc.

Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. In doing so, we seek to develop assets medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.

Tourmaline Bio

Tourmaline CEO Sandeep Kulkarni will take part in a fireside chat today at 1:00 PM ET at the Piper Sandler 35th Annual Virtual Healthcare Conference.

To listen to the webcast, please visit: https://lnkd.in/eGYp3Pb7
 
 #Tourmaline #Immunology #TeamTourmaline #PSCHealthcare2023

Tourmaline CEO Sandeep Kulkarni will take part in a fireside chat today at 3:50 PM ET at the Guggenheim Partners 5th Annual I&I Conference.
 
To listen to the webcast, please visit: https://lnkd.in/eGYp3Pb7
 
 #Tourmaline #Immunology #TeamTourmaline #Guggenheim

	Dec '21	Dec '22	Dec '23
net income	-47.83M -	-19.70M 58.81%	-42.12M 113.82%
depreciation and amortization	623K -	6K 99.04%	33K 450%
deferred income tax
stock based compensation		195K -	5.77M 2,858.46%
change in working capital	2.31M -	902K 61.04%	-168K 118.63%
accounts receivables
inventory
accounts payables	1.32M -	193K 85.41%	-44K 122.80%
other working capital	992K -	709 99.93%	-124 117.49%
other non cash items	4.83M -	12.14M 151.35%	8.95M 26.29%
net cash provided by operating activities	-39.99M -	-6.46M 83.85%	-28.08M 334.83%
investments in property plant and equipment	-2.44M -	-5.07M 107.96%	-56K 98.90%
acquisitions net		-5M -
purchases of investments	-275.88M -		-16.60M -
sales maturities of investments	181.93M -		20.50M -
other investing activites		-5K -	3.90K 177.92%
net cash used for investing activites	-96.39M -	-5.07M 94.74%	3.84M 175.77%
debt repayment		-150K -
common stock issued	137.68M -	20M 85.47%	70.47M 252.34%
common stock repurchased
dividends paid
other financing activites	-277K -	19.85K 107.17%	-5.71M 28,890.93%
net cash used provided by financing activities	137.40M -	19.85M 85.55%	156.72M 689.52%
effect of forex changes on cash
net change in cash	1.02M -	8.32M 712.10%	132.48M 1,491.53%
cash at beginning of period	17.59M -	150K 99.15%	8.47M 5,549.33%
cash at end of period	18.61M -	8.47M 54.48%	140.95M 1,563.36%
operating cash flow	-39.99M -	-6.46M 83.85%	-28.08M 334.83%
capital expenditure	-2.44M -	-5.07M 107.96%	-56K 98.90%
free cash flow	-42.42M -	-11.53M 72.83%	-28.14M 144.12%

TRML

COM:TOURMALINEBIO

Tourmaline Bio, Inc.

Last Close

22.72

22/11 21:00

Market Cap

590.04M

Beta: -

Volume Today

287.68K

Avg: -

Preview